Shanghai Zhimeng Biopharma Inc. was founded in 2018 by seasoned returnee scientists with over 30 years of biopharmaceutical R&D experience spanning both China and the U.S. The founding team possesses extensive and successful expertise in drug development for antiviral therapies (hepatitis B, hepatitis C, HIV), oncology, and neuropsychiatric disorders.
Zhimeng’s growth has been fueled by the trust and support of investment institutions. We are honored to collaborate with the following investors in the past. We look forward to working with more strategic partners for innovative, effective, safe, and affordable treatments, to achieve a functional cure, and to improve the quality of life of the patients.
Recent Investors
